Literature DB >> 26253531

Antibodies enhance CXCL10 production during RSV infection of infant and adult immune cells.

Marloes Vissers1, Inge Schreurs1, Jop Jans1, Jacco Heldens1, Ronald de Groot1, Marien I de Jonge1, Gerben Ferwerda2.   

Abstract

Respiratory syncytial virus (RSV) bronchiolitis is a major burden in infants below three months of age, when the primary immune response is mainly dependent on innate immunity and maternal antibodies. We investigated the influence of antibodies on innate immunity during RSV infection. PBMCs from infants and adults were stimulated with live RSV and inactivated RSV in combination with antibody-containing and antibody-depleted serum. The immune response was determined by transcriptome analysis and chemokine levels were measured using ELISA and flow cytometry. Microarray data showed that CXCL10 gene transcription was RSV dependent, whereas CXCL11 and IFNα were upregulated in an antibody-dependent manner. Although the presence of antibodies reduces RSV infection rate, it enhances the innate immune response. In adult immune cells, antibodies enhance CXCL10, CXCL11, IFNα and IFNγ production in response to RSV infection. Contrary, in infant immune cells only CXCL10 was enhanced in an antibody-dependent manner. Monocytes are the main source of CXCL10 and they produce CXCL10 in both an antibody- and virus-dependent manner. This study shows that antibodies enhance CXCL10 production in infant immune cells. CXCL10 has been implicated in exuberating the inflammatory response during viral infections and antibodies could therefore play a role in the pathogenesis of RSV infections.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; CXCL10; Infants; Innate immunity; RSV

Mesh:

Substances:

Year:  2015        PMID: 26253531     DOI: 10.1016/j.cyto.2015.07.024

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Transient Depletion of CD169+ Cells Contributes to Impaired Early Protection and Effector CD8+ T Cell Recruitment against Mucosal Respiratory Syncytial Virus Infection.

Authors:  Dong Sun Oh; Ji Eun Oh; Hi Eun Jung; Heung Kyu Lee
Journal:  Front Immunol       Date:  2017-07-13       Impact factor: 7.561

Review 2.  Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.

Authors:  Elisabeth A van Erp; Willem Luytjes; Gerben Ferwerda; Puck B van Kasteren
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

3.  Lack of Cell Cycle Inhibitor p21 and Low CD4+ T Cell Suppression in Newborns After Exposure to IFN-β.

Authors:  Jop Jans; Wendy W Unger; Elisabeth A M Raeven; Elles R Simonetti; Marc J Eleveld; Ronald de Groot; Marien I de Jonge; Gerben Ferwerda
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

4.  Species-specific transcriptomic changes upon respiratory syncytial virus infection in cotton rats.

Authors:  Britton A Strickland; Seesandra V Rajagopala; Arash Kamali; Meghan H Shilts; Suman B Pakala; Marina S Boukhvalova; Shibu Yooseph; Jorge C G Blanco; Suman R Das
Journal:  Sci Rep       Date:  2022-10-04       Impact factor: 4.996

5.  Actin- and clathrin-dependent mechanisms regulate interferon gamma release after stimulation of human immune cells with respiratory syncytial virus.

Authors:  Jop Jans; Hicham elMoussaoui; Ronald de Groot; Marien I de Jonge; Gerben Ferwerda
Journal:  Virol J       Date:  2016-03-22       Impact factor: 4.099

6.  RSV Infection in Human Macrophages Promotes CXCL10/IP-10 Expression during Bacterial Co-Infection.

Authors:  Daniela Machado; Jonathan Hoffmann; Marie Moroso; Manuel Rosa-Calatrava; Hubert Endtz; Olivier Terrier; Glaucia Paranhos-Baccalà
Journal:  Int J Mol Sci       Date:  2017-12-07       Impact factor: 5.923

7.  Siglec-1 inhibits RSV-induced interferon gamma production by adult T cells in contrast to newborn T cells.

Authors:  Jop Jans; Wendy W J Unger; Marloes Vissers; Inge M L Ahout; Inge Schreurs; Arthur Wickenhagen; Ronald de Groot; Marien I de Jonge; Gerben Ferwerda
Journal:  Eur J Immunol       Date:  2018-01-18       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.